AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25064594 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed paracetamol (maximum 4000 mg/day)
Number of subjects: 1652
Study 25064594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1652
Study 25064594 — intervention group
Group type: COMPARATOR
Intervention: Regular paracetamol vs placebo
Number of subjects: 1652
Study 25064594 — intervention group
Group type: COMPARATOR
Intervention: As-needed paracetamol vs placebo
Number of subjects: 1652
Study 25064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular paracetamol vs as-needed
Number of subjects: 1652
Study 25064594 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1652
Study 22056282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 1507
Study 22056282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507
Study 22056282 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal general anesthesia
Number of subjects: 1507
Study 22056282 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at birth increase (1-week increase)
Number of subjects: 1507
Study 18199496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200
Study 18199496 — intervention group
Group type: COMPARATOR
Intervention: Selectively invasive strategy
Number of subjects: 1200
Study 17848615 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment strategy
Number of subjects: 2079
Study 17848615 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment strategy
Number of subjects: 2079
Study 15752407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 50 mg every 8 hours
Number of subjects: 40
Study 15752407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12161404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly
Number of subjects: 138
Study 12161404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg/day for 7 days followed by fluconazole 150 mg once weekly
Number of subjects: 138
Study 12161404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 10534635 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 100
Study 10534635 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band (TL-01) phototherapy
Number of subjects: 100
Study 7819037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3,000 mg)
Number of subjects: 79
Study 7819037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 2080484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam drops
Number of subjects: 154
Study 2080484 — intervention group
Group type: COMPARATOR
Intervention: 10 mg prazepam tablets
Number of subjects: 154
Study 2080484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 7378213 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 11
Study 7378213 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 11
Study 7378213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30741193 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-Generated Questions (SGQs)
Number of subjects: 10
Study 30741193 — intervention group
Group type: COMPARATOR
Intervention: Faculty-Generated Questions (FGQs)
Number of subjects: 10
Study 28258251 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamyweb Intervention (self-sampling kits offered)
Number of subjects: 7215
Study 26091386 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dapsone gel
Number of subjects: 56
Study 26091386 — intervention group
Group type: COMPARATOR
Intervention: 0.75% metronidazole gel
Number of subjects: 56
Study 24999283 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic drug use identification
Number of subjects: 3240
Study 24999283 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of problematic drug use
Number of subjects: 3240
Study 24999283 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates among primary cannabis users
Number of subjects: 3240
Study 22831548 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based healthy lifestyle promotion campaign
Number of subjects: 4650
Study 22831548 — intervention group
Group type: COMPARATOR
Intervention: Conventional healthcare services (control)
Number of subjects: 4650
Study 19917377 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/d
Number of subjects: 66
Study 19917377 — intervention group
Group type: COMPARATOR
Intervention: Control (no losartan)
Number of subjects: 66
Study 17208103 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion using 18% hydrochloric acid and pumice technique
Number of subjects: 8
Study 15168099 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 18
Study 15168099 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 18
Study 15168099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16894712 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol
Number of subjects: 30
Study 16894712 — intervention group
Group type: COMPARATOR
Intervention: 15.5% ferric sulphate
Number of subjects: 30
Study 9640060 — intervention group
Group type: EXPERIMENTAL
Intervention: General Motor Activity evaluation during rehabilitation
Number of subjects: 0
Study 9640060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathew and Barthel scales
Number of subjects: 0
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. before meals
Number of subjects: 80
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. after meals
Number of subjects: 80
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. before meals (good compliers)
Number of subjects: 80
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg q.d.s. after meals (good compliers)
Number of subjects: 80
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Good compliance
Number of subjects: 80
Study 7865641 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor compliance
Number of subjects: 80
Study 1106446 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (15, 20, or 30 mg in hard gelatin capsules or 20 mg in soft gelatin capsules)
Number of subjects: 30
Study 1106446 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam (5 mg)
Number of subjects: 30
Study 1106446 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone sodium (100 mg)
Number of subjects: 30
Study 1106446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31439049 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaLife education program for relatives of diabetes patients
Number of subjects: 0
Study 31439049 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 28790412 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed degeneration method for investigating ligand recognition mechanisms of endothelin receptor type A (ETA) with endothelin-1 (ET-1)
Number of subjects: 0
Study 25565349 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-activating group (participants asked to think about their past throwing experience between trial blocks)
Number of subjects: 2
Study 25565349 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants maintained their performance across blocks)
Number of subjects: 2
Study 25565349 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-activating group (participants practicing a wiffleball hitting task)
Number of subjects: 2
Study 25565349 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants practicing a wiffleball hitting task)
Number of subjects: 2
Study 24053433 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid fluid loading for 90 min, guided by changes in pulmonary artery occlusion pressure (PAOP) or central venous pressure (CVP)
Number of subjects: 37
Study 24053433 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid fluid loading for 90 min, guided by changes in PAOP or CVP
Number of subjects: 37
Study 24053433 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SvO2
Number of subjects: 37
Study 24053433 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in GEDVI
Number of subjects: 37
Study 24053433 — intervention group
Group type: EXPERIMENTAL
Intervention: SvO2 increases
Number of subjects: 37
Study 22165032 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine during anesthesia and for 6 days after recovery from anesthesia
Number of subjects: 60
Study 22165032 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with oral lefoxidine 0.2 mg three times daily after recovery from anesthesia
Number of subjects: 60
Study 19368937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with Optisource (1109.3 kcal/day, 166.4g carbohydrates, 63g proteins, 21.3g lipids)
Number of subjects: 36
Study 19368937 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling with a decrease of 500 cal/day
Number of subjects: 36
Study 19368937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with Optisource
Number of subjects: 36
Study 19368937 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling
Number of subjects: 36
Study 16525139 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668
Study 16525139 — intervention group
Group type: COMPARATOR
Intervention: Control (no thalidomide)
Number of subjects: 668
Study 12393732 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccine administered before transplantation and at 3 months, 6 months, and 12 months post-transplantation
Number of subjects: 96
Study 12393732 — intervention group
Group type: COMPARATOR
Intervention: No vaccine administered before transplantation
Number of subjects: 96
Study 11246617 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (15 mg/day)
Number of subjects: 12
Study 11246617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9065635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral emedastine difumarate
Number of subjects: 45
Study 9065635 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride
Number of subjects: 45
Study 9065635 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao qing long tang (homeopathic decongestant)
Number of subjects: 45
Study 9065635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate aqueous nasal spray
Number of subjects: 45
Study 9065635 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-treatment measurements)
Number of subjects: 45
Study 8349380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic vectorcardiography
Number of subjects: 74
Study 8349380 — intervention group
Group type: COMPARATOR
Intervention: QRS scoring of the conventional 12-lead electrocardiogram
Number of subjects: 74
Study 2949309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen (100 mg in 5 ml)
Number of subjects: 10
Study 2949309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 ml)
Number of subjects: 10
Study 29497812 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol with ascorbic acid (PEG/Asc)
Number of subjects: 223
Study 29497812 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulfate with magnesium citrate (SP/MC)
Number of subjects: 223
Study 27391495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-plate-anchored face-mask therapy (n = 5)
Number of subjects: 11
Study 27391495 — intervention group
Group type: COMPARATOR
Intervention: Intermaxillary elastics to miniplates (n = 6)
Number of subjects: 11
Study 24191968 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated head injury
Number of subjects: 0
Study 24191968 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor effort on performance validity tests (PVTs)
Number of subjects: 0
Study 24191968 — intervention group
Group type: COMPARATOR
Intervention: Control group (valid performance on PVTs)
Number of subjects: 0
Study 22294268 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual temporal bone dissection system
Number of subjects: 80
Study 22294268 — intervention group
Group type: COMPARATOR
Intervention: Standard cadaveric temporal bones
Number of subjects: 80
Study 20858150 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 160
Study 20858150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 18446020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit/Min plus 4.5 g FOS plus 200 mg fish oil-derived DHA (DHA-FOS group)
Number of subjects: 144
Study 18446020 — intervention group
Group type: COMPARATOR
Intervention: Basic vitamin-mineral supplement (Vit/Min group)
Number of subjects: 144
Study 18446020 — intervention group
Group type: COMPARATOR
Intervention: Vit/Min plus 4.5 g fructo-oligosaccharide (FOS group)
Number of subjects: 144
Study 16339289 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (150 mg)
Number of subjects: 1609
Study 16339289 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (100 mg)
Number of subjects: 1609
Study 16339289 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly ibandronate (50 mg)
Number of subjects: 1609
Study 16339289 — intervention group
Group type: COMPARATOR
Intervention: Daily ibandronate
Number of subjects: 1609
Study 16339289 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1609
Study 15655620 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT screening
Number of subjects: 8963
Study 15655620 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy after positive FOBT
Number of subjects: 8963
Study 15655620 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-FOBT participants)
Number of subjects: 8963
Study 10659695 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) calls with telephone nurse follow-up
Number of subjects: 248
Study 10659695 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study 9147428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/behavioral skills‐building intervention (n = 199)
Number of subjects: 399
Study 9147428 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief standardized counseling session, n = 200)
Number of subjects: 399
Study 8401546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for 8 weeks
Number of subjects: 39
Study 8401546 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychoeducational interventions
Number of subjects: 39
Study 8401546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychological, pharmacologic, and experimental treatment approaches
Number of subjects: 39
Study 2946608 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery
Number of subjects: 90
Study 2946608 — intervention group
Group type: COMPARATOR
Intervention: Danazol therapy
Number of subjects: 90
Study 31420960 — intervention group
Group type: EXPERIMENTAL
Intervention: CET group (group aftercare)
Number of subjects: 164
Study 31420960 — intervention group
Group type: EXPERIMENTAL
Intervention: CET app (fully automated mobile phone app aftercare)
Number of subjects: 164
Study 31420960 — intervention group
Group type: COMPARATOR
Intervention: Aftercare as usual
Number of subjects: 164
Study 29017905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sensory play (fruit and non-food)
Number of subjects: 100
Study 29017905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-food sensory play
Number of subjects: 100
Study 29017905 — intervention group
Group type: COMPARATOR
Intervention: Fruit taste exposure
Number of subjects: 100
Study 29017905 — intervention group
Group type: COMPARATOR
Intervention: Control play
Number of subjects: 100
Study 27012407 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 36117
Study 27012407 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 36117
Study 23228587 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Training
Number of subjects: 45
Study 23228587 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy
Number of subjects: 45
Study 22905702 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% permethrin cream
Number of subjects: 220
Study 22905702 — intervention group
Group type: COMPARATOR
Intervention: 1% lindane lotion
Number of subjects: 220
Study 21253453 — intervention group
Group type: EXPERIMENTAL
Intervention: FFNS 110 mcg once daily
Number of subjects: 102
Study 21253453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 16835006 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (200 IU/day)
Number of subjects: 51
Study 16835006 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (225 IU/day)
Number of subjects: 51
Study 16835006 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH (200 IU/day)
Number of subjects: 51
Study 15134971 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Laser Prostatectomy (CLP)
Number of subjects: 141
Study 15134971 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 141
Study 15134971 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study 12067143 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (DP)
Number of subjects: 33
Study 9520929 — intervention group
Group type: EXPERIMENTAL
Intervention: brief behavioral intervention
Number of subjects: 36
Study 9520929 — intervention group
Group type: COMPARATOR
Intervention: wait list control
Number of subjects: 36
Study 7854360 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitfield's cream (3% salicylic acid and 6% benzoylic acid)
Number of subjects: 138
Study 7854360 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 138
Study 2913103 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for smoking management and lecture on smoking consequences; nicotine gum freely available to patients; stickers attached to charts; gum and reminders.
Number of subjects: 50
Study 2913103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum availability
Number of subjects: 50
Study 4330318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysostaphin nasal spray
Number of subjects: 0
Study 4330318 — intervention group
Group type: COMPARATOR
Intervention: Neosporin ointment
Number of subjects: 0
Study 4330318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg daily for 3–7 days)
Number of subjects: 75
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injection of methylprednisolone (40 mg, 1–3 days before vitrectomy)
Number of subjects: 75
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone in CD subsided eyes
Number of subjects: 75
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone in CD persistent eyes
Number of subjects: 75
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injection in CD subsided eyes
Number of subjects: 75
Study 30940887 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular injection in CD persistent eyes
Number of subjects: 75
Study 30940887 — intervention group
Group type: COMPARATOR
Intervention: CD subsided eyes
Number of subjects: 75
Study 30940887 — intervention group
Group type: COMPARATOR
Intervention: CD persistent eyes
Number of subjects: 75
Study 28662509 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH 500 U
Number of subjects: 6
Study 28662509 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH 1,000 U
Number of subjects: 6
Study 26355026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lipo-PGE1
Number of subjects: 60
Study 26355026 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lipo-PGE1
Number of subjects: 60
Study 26355026 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamin (MeCbl) alone
Number of subjects: 60
Study 23400279 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating and ranking task
Number of subjects: 911
Study 23400279 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance sheet
Number of subjects: 911
Study 23400279 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment
Number of subjects: 911
Study 23400279 — intervention group
Group type: COMPARATOR
Intervention: Rating and ranking
Number of subjects: 911
Study 21442823 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) assisted general anesthesia (group T)
Number of subjects: 40
Study 21442823 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 40
Study 19692805 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment directed to the large intestine meridian (LI 8 to LI 10)
Number of subjects: 60
Study 19692805 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture directed to the large intestine meridian (LI 8 to LI 10)
Number of subjects: 60
Study 17109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Number of subjects: 203
Study 17109680 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks
Number of subjects: 203
Study 17109680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 1.5 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Number of subjects: 203
Study 17109680 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (Peg‐IFN) alpha‐2b 0.75 microg/kg/week plus ribavirin 800 mg/day for 48 weeks (in patients with genotypes 1, 4, and 5)
Number of subjects: 203